Vitro Diagnostics Inc. (fka VODG)

[Potse]

Wound care products...interview statements.....

According to Tuesday's (1/29/2013) blog post on the Vitro Biopharma website, the company is developing a wound healing product using mesenchymal stem cells.....

......Vitro Biopharma is now developing a MSC-based wound healing product and plans animal testing of this product in the near future.

The above statement in bold is from the January 2013 blog post on VODG's website. That single sentence was until this latest interview with James Musick the only public mention that Vitro Biopharma was developing a wound care product. So this product development initiative has been flying pretty much under the radar screen of most investors.

According to the interview Musick says development of the initial product is close to completion (item #1 below). But what I found particularly curious/interesting is another statement he made about the wound care product (item #2 below).

Interpretration of that statement is open for debate, but it almost looks to me that Musick is somewhat hinting/suggesting that VODG might license a drug/cell delivery technology from James Posillico. That would make for a pretty interesting 8-K and press release, and probably raise a few eyebrows.

One company that Posillico has been associated with in the last couple/few years is Polymer Therapeutics, LLC, and it does have delivery technologies......

http://polymerx.com/team/
http://polymerx.com/technology/

From the interview.....

1)

Another current objective is applying stem cell technology to advance regenerative medicine. I think we should be close to completion of the development of our initial products for use in accelerated wound healing.

2)

We have other collaborators that are very important to us too. Dr. Jim Posillico is a long-term colleague of mine. He is the licensee of our FSH technology & products. He is also involved in some new activities that complement our regenerative medicine initiative. He is licensing in technology that would provide very critical drug delivery and cell delivery methodologies for especially wound care products that we have in our pipeline as well as other delivery processes.